Veeva Systems received a Buy rating due to its accelerating revenue growth, impressive 45% operating margins, and strong customer retention in regulated software. Although trading at a 70% price-to-earnings premium compared to its sector, the valuation remains below its five-year average with a favorable PEG ratio. Key recent wins include major biopharma CRM contracts and adoption of its clinical applications by IQVIA. Investors should watch upcoming guidance for 2028, R&D and quality growth, and the upcoming Investor Day for future valuation insights.
Veeva Systems trades at USD 302.50 on Pluang as of Nov 04, 2026 05:21 WIB, close to its 52-week high of USD 323.04 and well above its 52-week low of USD 151.43. Despite a 1.47% dip in the last day, the stock maintains a strong market cap of $49.71 billion. This price level highlights Veeva's premium valuation compared to its sector, consistent with the article's note on its price-to-earnings premium but below its five-year average valuation.
Veeva Systems has earned a buy rating due to re-accelerated growth in its core business segments, including a 13% year-over-year increase in its Commercial Solutions subscriptions and a robust 19.3% growth in R&D and Quality segments. The company ben...
Veeva Systems reported fiscal Q2 revenue of $928 million, marking an 18% year-over-year increase, alongside a 40% rise in GAAP operating income. The company retained 70% of its biopharma CRM subscription base and secured all four undecided top-20 acc...
